SLS SELLAS Life Sciences Group, Inc.
Healthcare$8.12+4.37%ClosedMarket Cap: $1.16B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
12.49
P/S
0.00
EV/EBITDA
-42.07
DCF Value
$0.63
FCF Yield
-2.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-47.1%
ROA
-25.8%
ROIC
-29.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | NaN% | $-9.3M | $-8.4M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.3M | $-7.7M | $— | — |
| FY null | $0.00 | NaN% | $-28.3M | $-26.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.1M | $-6.8M | $— | — |
| Q2 null | $0.00 | NaN% | $-6.9M | $-6.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-6.1M | $-5.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-6.9M | $-6.7M | $— | — |
| FY null | $0.00 | NaN% | $-31.5M | $-30.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-7.3M | $-7.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-7.6M | $-7.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-9.6M | $-9.6M | $— | — |
| Q4 2023 | $0.00 | NaN% | $-8.2M | $-8.1M | $-0.26 | — |